What is Kidney Transplant Phase 3 Belatacept BENEFIT?

Category: Others

false

See also: Clinical Trial

NCT00256750 is belatacept evaluation of nephroprotection and efficacy as first-line immunosuppression trial. Other study IDs include: IM103-008, BENEFIT.

Reported purpose & perceived effectiveness
Purpose Patients Patients with evaluations Perceived Effectiveness
Transplant rejection prevention 2 1

  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

side_effects of Kidney Transplant Phase 3 Belatacept BENEFIT"

Severe
0
Moderate
0
Mild
0
None
1

Dosages

Most common dosages (by patients currently using Kidney Transplant Phase 3 Belatacept BENEFIT)
Dosage Patients
500 mg monthly 1
750 mg monthly 1
500 mg every other week 1
Adherence
Always
1 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%
Burden
Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
1 100%
Cost
$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
1 100%
Last updated:
There are no evaluations for Kidney Transplant Phase 3 Belatacept BENEFIT.